Prostate-specific membrane antigen (PSMA) PET-CT imaging in the investigation and management of biochemical recurrence in prostate cancer.

Published on Feb 26, 2018in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.2018.36.6_SUPPL.208
Fergus Keane1
Estimated H-index: 1
(Mater Misericordiae Hospital),
Yasser Ged3
Estimated H-index: 3
(University Hospital Waterford)
+ 3 AuthorsJohn McCaffrey16
Estimated H-index: 16
(Mater Misericordiae University Hospital)
Sources
Abstract
208Background: It is estimated that within ten years of primary treatment for prostate cancer up to 40% of patients post radical prostatectomy, and up to 50% of patients post radiotherapy will develop disease recurrence. While monitoring of PSA levels is informative of biochemical recurrence, it may precede radiologically detectable recurrence by months to years, and cannot differentiate local/regional recurrence from systemic disease. This represents a management dilemma for treating physicians. The incorporation of PET probes targeting prostate-specific membrane antigen (PSMA) for prostate cancer shows promise for improving the management of patients with prostate cancer, when used alongside existing imaging techniques, like CT, MRI and bone scans. Methods: Retrospective review of all patients referred from our institution for PSMA imaging was carried out. Baseline clinical features were determined and we analyzed impact of PSMA imaging on management outcomes and survival data. Results: 33 patients refe...
📖 Papers frequently viewed together
43 Citations
51 Citations
11 Citations
References0
Newest
Cited By2
Newest
#1Ao LiuH-Index: 4
#2Lu ChenH-Index: 8
Last. Danfeng Xu (SJTU: Shanghai Jiao Tong University)H-Index: 10
view all 9 authors...
Prostate-specific membrane antigen positron emission tomography (PSMA PET) is a promising imaging modality for detection of biochemical recurrent prostate cancer (BRPCa). This systematic review and meta-analysis was to summarize the impact of PSMA PET on the management of BRPCa patients based on prospective studies. According to the PRISMA statement, articles in Pubmed and Embase were searched till May 26th, 2020 to identify eligible prospective studies that reported changes in the management of...
Source
#1M I Ross (University of Cambridge)H-Index: 1
#2N. Bird (Cambridge University Hospitals NHS Foundation Trust)H-Index: 1
Last. Y L Rimmer (Cambridge University Hospitals NHS Foundation Trust)H-Index: 1
view all 4 authors...
Brain metastases from prostate cancer are rare and usually only occur in the context of widespread systemic disease. This is the first case report of a solitary brain oligometastasis, in a neurologically intact prostate cancer patient with no other systemic disease, detected using [68Ga]Ga-THP-PSMA PET/CT and only the second one using a PSMA-based radiopharmaceutical. We report the case of a prostate cancer patient presenting 5 years after robot-assisted laparoscopic prostatectomy with biochemic...
1 CitationsSource